Cannabis Law Report

JUNE 2, 2021

Researchers studying the efficacy of marijuana treatments for veterans’ mental health now have access to $20 million in marijuana tax revenue to fund clinical trials. Department of Veteran Affairs’ most recent data. The deadline for proposals is Friday, July 16. The deadline for proposals is Friday, July 16. Between Dec.

Clinical Trials 105

Clinical Trials Marijuana Recreational Collective 105

Cannabis Law Report

SEPTEMBER 7, 2022

According to patient data, over 50 per cent of patients at Cantourage Clinic mention anxiety as their primary or secondary indication. The clinic has experienced an exceptional level of demand for medical cannabis treatments concerning anxiety and a variety of other psychiatric conditions. .

Patients 52

Patients Conditions Treatment Education 52

Veriheal

JANUARY 26, 2023

A team of researchers, who presented their study results during the Neuroscience 2022 conference , demonstrated that cannabis improves mental performance while reducing risky decision-making, a symptom commonly associated with bipolar disorder. Talk to a medical cannabis doctor to determine a good treatment plan for your symptoms.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

Veriheal

AUGUST 23, 2023

Over the span of a month, the participants were closely monitored, providing a total of 192 observations to form a robust data set. In June 2022, a study offered compelling evidence that taking microdoses of psilocybin mushrooms had a beneficial impact on mood.

Microdosing 98

Microdosing Data Treatment Conditions 98

Veriheal

JUNE 19, 2023

The psychedelic drugs here include LSD, MDMA, psilocybin, ketamine, and ayahuasca, which are in high demand for mental health treatment and other therapeutic reasons. As of 2022, the global psychedelics market was valued at $4.87 billion in the next six years. .” Why Is the Psychedelics Market Growing?

Therapy 109

Therapy Treatment Patients Policy 109

Veriheal

AUGUST 31, 2022

Nonetheless, the data speaks differently. . The research letter written by Dr. Harocopos and his team looked into the first two months of OPC operation by collecting data from program staff on individuals using the services at the two OPC sites. 31, 2022, 78% identified as male, 36.9% The Research Letter. 30, 2021, and Jan.

Consumption 104

Consumption Data Treatment Collective 104

Cannabis Law Report

JULY 25, 2022

The data from this study is currently being assembled and MindBio is set to further announce the new findings. 10,000 microdoses of LSD will fit into this tiny bottle but could help up to 60 patients who suffer from Mental Health issues. — MindBio Therapeutics (@MindBioTherap) July 10, 2022.

Microdosing 52

Microdosing Clinical Trials Research and Development Data 52

Cannabis Law Report

APRIL 14, 2022

These facilities can also take a toll on water treatment facilities that were not designed for (and do not monitor for) cannabis waste products, fertilizers, and pesticides. Next Steps. As the cannabis industry matures, more regulation is sure to follow and, with that, additional risks and opportunities.

Environment 52

Environment Agriculture Compliance Compliance 52

Cannabis Law Report

JANUARY 3, 2022

The Czech Republic legalized therapeutic cannabis for selected patients in 2015, and health insurance companies have been covering up to 90% of the cost of the treatment since 2020. According to official data cited by the Czech News Agency (CTK), the treatment helped improve the health condition and well-being of patients in 69% of cases.

Media 52

Media Chronic Pain Patients Treatment 52

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. US Provisional Patent Filed. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

APRIL 13, 2022

The Center Square) – Marijuana sales in Colorado continued a downward trend in February totaling $145 million, according to the state’s latest market data. New Report Format in 2022! The monthly reports are now replaced with two reports that have data from every month since 2014. Marijuana Sales Report, 2014 to Date.

Marijuana 52

Marijuana Data Retail Collective 52

Cannabis Law Report

JUNE 19, 2022

Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time. Dr. Nick Allen, co-founder and CEO of Ksana Health, commented: “Psychedelic treatments are offering exciting new approaches to recovery from mental disorders.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Veriheal

MAY 17, 2023

According to the 2022 Legislative Finance Committee Corrections Department Performance Report Card, about 35% of detentions in the state’s corrections department were for technical parole offenses. .” Ideally, people grappling with the effect of substance use disorder should be given treatment and assistance, not jailed.

Treatment 98

Treatment Policy Legislation Collective 98

Cannabis Law Report

MARCH 11, 2022

10 March 2022. The Technical Note “Management of Cannabis Waste in the context of activities that produce cannabis for medicinal purposes” was published on 8 February 2022. It became necessary to establish a legal framework to manage cannabis waste, in particular, its classification, transportation and treatment.

Medicine 52

Medicine Treatment Packaging Digestion 52

Cannabis Law Report

APRIL 21, 2022

and Canada highlights mounting cases of cannabis poisoning among pets and sheds new light on symptoms, treatments, and outcomes. Richard Quansah Amissah of the Ontario Veterinary College at the University of Guelph in Ontario, Canada, and colleagues present these findings in the open-access journal PLOS ONE on April 20, 2022.

Pets 52

Pets Research and Development Topical Consumption 52

Cannabis Law Report

AUGUST 18, 2022

Smith , a partner with the firm and co-leader of the firm’s Life Sciences & Health Effects Team, will lead the practice, bringing together scientist-attorneys and experienced litigators to support clients that are driving innovation in mental health treatments. BUFFALO, N.Y. , Aug. Tweet this. However, change appears imminent.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

MAY 10, 2022

11 May 2022. First academic study of national medicinal cannabis data. Using data from the Therapeutic Goods Administration (TGA) – Australia’s Special Access Scheme B, the researchers found the other two top reasons for prescriptions were pain and sleep disorders. Here’s the Uni of Sydney press release.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Brian Schatz & Cory Booker to Acting Director Tabak and Commissioner Califf (May 11, 2022), [link]. [2] Defining Psychedelics.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Veriheal

JUNE 30, 2023

Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment. The 14-page document covers several aspects of the drug development process, including trial best practices, data collection, and new drug application requirements.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

JANUARY 21, 2022

Supreme Court to hear her appeal over coverage of medical marijuana treatments, as reported in the article “ U.S. AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Copyright © 2022 by A.M. For more information, visit www.ambest.com. Best Company, Inc.

Treatment 52

Treatment Data Business Access 52

Canna Law Blog

DECEMBER 21, 2023

Sales fell (again) along with licensee numbers (for the first time) According to OLCC data , retail sales between January 1, 2023 and November 30, 2023 clocked in at $874 million. decrease from $994 million in 2022, which itself was the first calendar year cannabis sales contracted in Oregon. That tally would be a 4.1%

Hemp 86

Hemp Retail Compliance Compliance 86

Veriheal

DECEMBER 23, 2022

Dr. Maxwell’s team also collected data contained in samples sourced from California. After a close analysis of the data, the team determined that an absence of consistent federal guidelines regarding marijuana contaminants ultimately increases the risk of consumers developing health issues. 74 solvents. 21 microbes.

Research and Development 96

Research and Development Agriculture Data Extraction 96

Cannabis Law Report

OCTOBER 22, 2021

Food and Drug Administration (“FDA”) standards have been initiated in preparation for human clinical studies, expected in early 2022; and. Cybin continues to demonstrate superior properties of its CYB003 and CYB004 programs as we progress toward first-in-human studies, expected in early 2022.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

JULY 24, 2022

The market launch of drugs containing MDMA for post-traumatic stress disorder (PTSD) or psilocybin for the treatment of depression is expected in the next five to ten years [1]. The market research company Data Bridge Market Research projects that the market capitalization of the psychedelic industry will grow 16.8 billion by 2029.

Research and Development 52

Research and Development Legalization Treatment Patients 52

Veriheal

DECEMBER 27, 2022

The subjective nature of self-reported data can plague research. In an August 2022 study published by the Journal of the American Medical Association (JAMA) , psilocybin appears to be an effective tool for reducing problematic alcohol consumption. However, it does suggest a strong association between the two.

Research and Development 101

Research and Development Therapy Consumption DEA 101

Veriheal

MARCH 8, 2022

Adults age 21 and over have been legally allowed to purchase a maximum of one ounce of recreational cannabis in Montana since January 1, 2022. Furthermore, data released by the Montana Department of Revenue indicates that statewide recreational cannabis sales remained level through the month of January – resting somewhere between $2.6

Programs 98

Programs Recreational Edibles Tincture 98

Cannabis Law Report

JUNE 8, 2022

Published: Jun 07, 2022. MDMA-assisted therapy, a novel treatment for PTSD with FDA breakthrough therapy designation, is on track for NDA submission in 2023 pending results of the confirmatory Phase 3 trial. to serve on its Board of Directors, effective June 2, 2022. He holds a Ph.D. from Princeton University and a B.A.

Therapy 52

Therapy Treatment Access Patients 52

Cannabis Law Report

AUGUST 24, 2022

25 August 2022. The data suggests we have seen a transition from illicit to legal use of medical cannabis, ” said lead researcher Professor Nicholas Lintzeris , from the Faculty of Medicine and Health at the University of Sydney. Results from the third Cannabis as Medicine study.

Medicine 52

Medicine Legalization Chronic Pain Access 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JANUARY 12, 2022

Through the partnership, Maya’s Real World Evidence Platform will be one of the core services offered to the association’s members when it officially launches in Q4 of 2022. Through the right mix of regulation, technology, and data, both are equally achievable,” says NPA CEO Britt Rollins. ABOUT MAYA.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

The Cannigma

OCTOBER 17, 2022

A 2022 systematic review and meta-analysis also offered insights into whether cannabis use during pregnancy leads to lower birth weight, preterm birth, or smallness for gestational age. The meta-analysis reviewed 32 studies containing data from approximately 5.5 million women.

Research and Development 88

Research and Development Data THC Cannabis 88

Cannabis Law Report

AUGUST 12, 2022

In both his testimony and written comments , Jonathan praised policymakers’ mission to regulate intoxicating compounds as adult-use cannabis, but raised objections to the treatment of hemp products—with any amount of THC—with burdensome restrictions, such as age limits. Here’s some local coverage of the hearing.

Hemp 52

Hemp THC Food Legislation 52

Cannabis Law Report

JANUARY 4, 2022

Medical marijuana treatment centers like Gold Leaf are the only businesses currently authorized to cultivate, process, and dispense low-THC cannabis and medical marijuana in Florida. Agrify brings data, science, and technology to its customers for unparalleled control over cultivation and extraction. BILLERICA, Mass., BILLERICA, Mass.,

Extraction 52

Extraction Cultivation Programs Data 52

Cannabis Law Report

DECEMBER 20, 2021

The new amendments, which will take effect as of January 2, 2022, came to balance between deterrent punishment and rehabilitation of the abuser. This data is prohibited in other than cases stipulated by the law from disclosing or broadcasting.

Law 52

Law Data Treatment Patients 52

The Cannigma

AUGUST 5, 2022

Of the people who take antidepressants, 30% won’t respond to treatment. But what other options do people suffering from depression, particularly treatment-resistant depression, have? What is ketamine treatment? Ketamine treatment for depression may be one of the biggest leaps forward in mental healthcare in decades.

Treatment 138

Treatment Research and Development Therapy Digestion 138

Cannabis Law Report

MARCH 17, 2022

COVID-related border restrictions did not cause immediate major interruption to Australia’s drug markets, but wastewater data strongly indicates that the cumulative effect of these restrictions led to some substantial market interruptions. 15 March 2022. The latest report presents data on Australia’s drug consumption for 12 substances.

Consumption 52

Consumption Programs Data Treatment 52